The present invention provides corrosion inhibiting compositions that incorporate at least one bis-imidazoline compound. In the practice of the present invention, a tetramine admixture enriched with respect to linear tetramine is used to prepare the bis-imidazoline compound. Enriched means at least 70 weight percent and up to 100% of the tetramine species included in the admixture includes a linear tetramine such as L-TETA.

This invention relates to 4-substituted isoquinoline compounds and their derivatives and uses thereof for treatment of cancer, for example, acute myeloid leukemia.

This invention relates to 4-substituted isoquinoline compounds and their derivatives and uses thereof for treatment of cancer, for example, acute myeloid leukemia.

Described herein are liver X receptor (LXR) modulators and methods of utilizing LXR modulators in the treatment of LXR-associated diseases, disorders or conditions. Also described herein are pharmaceutical compositions containing such compounds.

This describes homogeneous catalysts that are recoverable from solution by being phase selective and through host-guest interactions. An example of a method includes separating a water soluble N-heterocyclic carbene homogeneous catalyst from a solution by: (a) forming a host-guest compound between the catalyst and an inclusion compound in the solution; and (b) isolating the host-guest compound from the solution.

Described herein are liver X receptor (LXR) modulators and methods of utilizing LXR modulators in the treatment of LXR-associated diseases, disorders or conditions. Also described herein are pharmaceutical compositions containing such compounds.

Described herein are liver X receptor (LXR) modulators and methods of utilizing LXR modulators in the treatment of LXR-associated diseases, disorders or conditions. Also described herein are pharmaceutical compositions containing such compounds.

A stabilized imidazoline complex includes a proton-stabilizing molecule and a positively charged imidazoline compound, where the proton-stabilizing molecule has a first lone-pair-bearing atom and a second lone-pair-bearing atom. The proton-stabilizing molecule is a dye. The positively charged imidazoline compound includes an imidazoline ring and a hydrogen atom, and a covalent bond connects the hydrogen atom with a nitrogen atom of the imidazoline ring. At least one hydrogen bond connects the hydrogen atom with the first lone-pair-bearing molecule and the second lone-pair-bearing atom of the proton-stabilizing molecule.

A stabilized imidazoline complex includes a proton-stabilizing molecule and a positively charged imidazoline compound, where the proton-stabilizing molecule has a first lone-pair-bearing atom and a second lone-pair-bearing atom. The proton-stabilizing molecule is a dye. The positively charged imidazoline compound includes an imidazoline ring and a hydrogen atom, and a covalent bond connects the hydrogen atom with a nitrogen atom of the imidazoline ring. At least one hydrogen bond connects the hydrogen atom with the first lone-pair-bearing molecule and the second lone-pair-bearing atom of the proton-stabilizing molecule.

Described herein are liver X receptor (LXR) modulators and methods of utilizing LXR modulators in the treatment of LXR-associated diseases, disorders or conditions. Also described herein are pharmaceutical compositions containing such compounds.